237 related articles for article (PubMed ID: 9013476)
1. Detection of minimal residual disease in multiple myeloma and acute leukaemia.
Bakkus MH; Juge-Morineau N; van der Werff ten Bosch JE
Med Oncol; 1996 Jun; 13(2):121-31. PubMed ID: 9013476
[TBL] [Abstract][Full Text] [Related]
2. Detection of minimal residual disease.
Deptala A; Mayer SP
Methods Cell Biol; 2001; 64():385-420. PubMed ID: 11070849
[No Abstract] [Full Text] [Related]
3. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis of minimal residual disease in autologous bone marrow transplantation].
Jørgensen H; Bukh A; Hokland P; Ellegaard J; Madsen PS; Hokland M
Nord Med; 1996 Dec; 111(10):344-7. PubMed ID: 8992466
[TBL] [Abstract][Full Text] [Related]
5. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
6. Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders.
Corradini P; Carniti C
Methods Mol Biol; 2014; 1109():209-37. PubMed ID: 24473786
[TBL] [Abstract][Full Text] [Related]
7. Assessment of minimal residual disease in patients with acute leukemia.
Baer MR
Curr Opin Oncol; 1998 Jan; 10(1):17-22. PubMed ID: 9466480
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease monitoring in multiple myeloma.
Davies FE; Rawstron AC; Owen RG; Morgan GJ
Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
[TBL] [Abstract][Full Text] [Related]
9. Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.
McAuliffe S; Brown R; Catalano A; Ho PJ; Nassif N; Woodland N; Hart D; Weatherburn C; Yang S; Suen H; Paul C; Joshua D; Gibson J
Leuk Lymphoma; 2015; 56(9):2714-6. PubMed ID: 25651422
[No Abstract] [Full Text] [Related]
10. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma.
Ladetto M; Donovan JW; Harig S; Trojan A; Poor C; Schlossnan R; Anderson KC; Gribben JG
Biol Blood Marrow Transplant; 2000; 6(3):241-53. PubMed ID: 10871149
[TBL] [Abstract][Full Text] [Related]
11. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.
Rasmussen T; Poulsen TS; Honoré L; Johnsen HE
Exp Hematol; 2000 Sep; 28(9):1039-45. PubMed ID: 11008016
[TBL] [Abstract][Full Text] [Related]
13. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients.
Powles R; Sirohi B; Kulkarni S; Bhagwati N; Saso R; Raje N; Horton C; Singhal S; Mehta J; Treleaven J
Bone Marrow Transplant; 2000 May; 25(9):949-56. PubMed ID: 10800062
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease in leukaemia patients.
Szczepański T; Orfão A; van der Velden VH; San Miguel JF; van Dongen JJ
Lancet Oncol; 2001 Jul; 2(7):409-17. PubMed ID: 11905735
[TBL] [Abstract][Full Text] [Related]
15. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia.
Matsushita M; Ikeda H; Kizaki M; Okamoto S; Ogasawara M; Ikeda Y; Kawakami Y
Br J Haematol; 2001 Mar; 112(4):916-26. PubMed ID: 11298586
[TBL] [Abstract][Full Text] [Related]
16. Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma.
Martinez-Lopez J; Martinez-Sanchez P; Garcia-Sanz R; Sarasquete ME; Ayala R; Gonzalez M; Bautista JM; Gonzalez D; San Miguel J; Garcia-Effron G; Lahuerta JJ
J Mol Diagn; 2006 Jul; 8(3):364-70. PubMed ID: 16825510
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease detection in myeloma: no more molecular remissions?
Rawstron AC
Haematologica; 2005 Oct; 90(10):1300B. PubMed ID: 16219557
[No Abstract] [Full Text] [Related]
18. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
[TBL] [Abstract][Full Text] [Related]
19. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M
Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N; Zagrivnaja M; Schwartz S; Badbaran A; Zabelina T; Lioznov M; Ayuk F; Zander A; Fehse B
Exp Hematol; 2006 May; 34(5):688-94. PubMed ID: 16647575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
